BACKGROUND: Pathogen reduction treatment (PRT) reduces the risk of transfusion-transmitted infections from established and emerging organisms. Manufacturing, however, is complex. In our university health system, we phased in pathogen-reduced platelets (PR PLTs) by patient population. We then assessed the implementation strategy and investigated factors in the supply chain that prevented us from meeting the goal of providing greater than 90% PR PLTs within 6 months. ABBREVIATIONS: BMT = bone marrow transplant; CMV = cytomegalovirus; FDA = US Food and Drug Administration; LIS = laboratory information system; PR PLTs = pathogen-reduced platelets; PRT = Pathogen reduction treatment; SOPs = standard operating procedures; UCSD = University of California San Diego. From the